Endo International plc

From Wikipedia, the free encyclopedia
  (Redirected from Endo Health Solutions)
Jump to: navigation, search
Endo International plc
Public
Traded as NASDAQENDP
S&P 400 Component
Industry Pharmaceutical
Headquarters Dublin, Ireland and Malvern, Pennsylvania, U.S.
Website www.endo.com

Endo International plc is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.[1]

Acquisitions[edit]

In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[2] The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.[2]

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.[3][4]

In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion.[5]

In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.[6]

Acquisition attempts[edit]

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.[7] However, Teva prevailed in this acquisition with a substantially higher bid.[8]

Opioids[edit]

Endo is one of the companies named in lawsuits by the states of Ohio[9], Missouri and Mississippi[10] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.[11]

See Also[edit]

References[edit]

  1. ^ Schneiderman, R.M. (9 April 2007). "Ammon Exits Endo". Forbes. 
  2. ^ a b Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28. 
  3. ^ Rubin, Ben Fox (5 November 2013). "Endo Health to Buy Paladin Labs for $1.6 Billion". Wall Street Journal. 
  4. ^ "Endo Health to Buy Specialty Drug Maker for $1.6 Billion". New York Times Dealbook. November 5, 2013. 
  5. ^ "Endo Scores with $2.6B Offer for Auxilium, Which Ends QLT Deal | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN". GEN. October 9, 2014. 
  6. ^ Bray, Chad (18 May 2015). "Endo International to Pay $8.05 Billion for Par Pharmaceutical". The New York Times. 
  7. ^ "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (2). January 15, 2014. p. 10. 
  8. ^ "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 10. 
  9. ^ Dwyer, Colin (31 May 2017). "Ohio Sues 5 Major Drug Companies For 'Fueling Opioid Epidemic'". NPR Online. 
  10. ^ Raymond, Nate (21 Jun 2017). "Missouri sues opioid manufacturers, joining two other U.S. states". Reuters. 
  11. ^ "Eondo Pharmaceuticals, FORM 10-K". 31 Dec 2016. 

External links[edit]